No Data
Express News | [Change Report] SBI Investment reports that the Shareholding percentage of Kepharma (4896.JP) has decreased to 15.1%.
Express News | [Change Report] SBI Investment reported a decrease in Shareholding of Kepharma (4896.JP) to 17.08%.
Express News | [Change Report] Itochu Technology Ventures reports a decrease in Shareholding of Keipharma (4896.JP) to 2.02%.
Kei Pharma - Extension of the joint research contract with Kitasato Institute regarding hearing disorders.
Kei Pharma <4896> announced on the 28th that it will extend its collaborative research contract with Kitasato Institute on hearing disorders until March 2026. The research group led by Professor Masato Fujioka from Kitasato University's School of Medicine, along with the company, has achieved certain results regarding the new efficacy of specific compounds in a hearing loss model using human iPS cell-derived inner ear cells. The extension of this collaborative research contract will allow for the acquisition of concrete data necessary for the implementation of corporate clinical trials and the start of the trials.
Even with the start of the new fiscal year, active buying of leading stocks is likely to continue to be restrained.
This week, trading will primarily focus on short-term investments in bio-related stocks and IPOs as the new fiscal year begins. However, due to the implementation of additional tariffs by the US on April 2, along with strong concerns about the subsequent impact on the real economy, it is believed that active buying cannot be expected given the prevailing uncertainty. The Emerging Markets, centered on domestic demand, seem to be relatively stable compared to the Main Board market, but there is no feeling that the main indices in the Growth market will rise significantly. The Growth Market 250 Index has narrowed its gains.
K Pharma: Extraordinary Report